Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Once-weekly, Repeated Dose, Placebo Controlled, Double Blind, Randomised Cross-over Trial Investigating Safety, Efficacy and Pharmacodynamics of FE 203799 in Patients With Short Bowel Syndrome With Intestinal Failure Requiring Parenteral Support Followed by an Additional Treatment Period in an Open Label Regimen.

Trial Profile

A Once-weekly, Repeated Dose, Placebo Controlled, Double Blind, Randomised Cross-over Trial Investigating Safety, Efficacy and Pharmacodynamics of FE 203799 in Patients With Short Bowel Syndrome With Intestinal Failure Requiring Parenteral Support Followed by an Additional Treatment Period in an Open Label Regimen.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs Apraglutide (Primary)
  • Indications Short bowel syndrome
  • Focus Adverse reactions
  • Sponsors GLyPharma Therapeutic; Therachon
  • Most Recent Events

    • 17 Jan 2019 A new treatment period 3 (Part B) has been added in study and it is an open label extension to part A that will test a new dose and dose for FE203799 Part A has also changed from 25mg to 5 mg.
    • 17 Jan 2019 Planned End Date changed from 1 Apr 2019 to 1 Sep 2019.
    • 17 Jan 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top